3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
34
Genitourinary
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Endocrine
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Somatostatinoma
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Insulinoma
1
Glucagonoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastrinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Islet Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Fluorodeoxyglucose F18
3
Trastuzumab
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
FAPI-46
2
Everolimus
2
tipifarnib
1
sargramostim
1
regorafenib
1
lanreotide
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
exemestane
1
entinostat
1
cabozantinib
1
aldesleukin
1
Tirapazamine
1
Tamoxifen
1
Surveys and Questionnaires
1
Sorafenib
1
Rose Bengal
1
Radiotherapy
1
Radiosurgery
1
Radiofrequency Ablation
1
Quality of Life
1
Oxaliplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
regorafenib
×
Endocrine
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled